The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STM-01: Phase I EffTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
 
Hiral A. Shah
No Relationships to Disclose
 
Sonia Christian
No Relationships to Disclose
 
Bilawal Ahmed
No Relationships to Disclose
 
Rozina A. Chowdhery
No Relationships to Disclose
 
Neeta K. Venepalli
No Relationships to Disclose
 
Oana Cristina Danciu
No Relationships to Disclose
 
Arkadiusz Z. Dudek
Leadership - IGF Oncology
Stock and Other Ownership Interests - Biothera; IGF Oncology; Vanquish Oncology
Honoraria - Biothera; IGF Oncology; Medtronic; Superlab Far East; Vanquish Oncology
Consulting or Advisory Role - Superlab Far East; Vanquish Oncology
Travel, Accommodations, Expenses - Superlab Far East